Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors

Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rye, Inga H., Trinh, Anne, Sætersdal, Anna B., Nebdal, Daniel, Lingjærde, Ole Christian, Almendro, Vanessa, Polyak, Kornelia, Børresen‐Dale, Anne‐Lise, Helland, Åslaug, Markowetz, Florian, Russnes, Hege G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210052/
https://www.ncbi.nlm.nih.gov/pubmed/30133130
http://dx.doi.org/10.1002/1878-0261.12375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210052/
https://www.ncbi.nlm.nih.gov/pubmed/30133130
http://dx.doi.org/10.1002/1878-0261.12375

Ejemplares similares